Part 1: Targeting Cancer Pathways: Tumor Resistance
You can also watch Part 2, Part 3, and Part 4 in this series.
You can also watch Part 2, Part 3, and Part 4 in this series.
Originally aired: Wednesday, October 22, 2014
This webinar is the first in a series focusing on the pathways that allow for cancer development and progression, the emerging research in identifying and targeting these pathways, and the innovations in the development of cancer treatment options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within cancerous cells. Instead, tumors should be considered complex tissues in which the cancer cells evolve and communicate with the surrounding cellular microenvironment to promote their own survival and dissemination. Although therapies against specific signaling proteins or pathways have been remarkably successful at treating certain cancers, the tumors frequently develop resistance, leading to even more aggressive forms of the disease. This webinar will focus on how rewiring of signaling pathways in response to drug treatment contributes to resistance and how this knowledge can be leveraged to develop more effective treatment strategies.
During this webinar, viewers will:
This webinar is the first in a series focusing on the pathways that allow for cancer development and progression, the emerging research in identifying and targeting these pathways, and the innovations in the development of cancer treatment options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within cancerous cells. Instead, tumors should be considered complex tissues in which the cancer cells evolve and communicate with the surrounding cellular microenvironment to promote their own survival and dissemination. Although therapies against specific signaling proteins or pathways have been remarkably successful at treating certain cancers, the tumors frequently develop resistance, leading to even more aggressive forms of the disease. This webinar will focus on how rewiring of signaling pathways in response to drug treatment contributes to resistance and how this knowledge can be leveraged to develop more effective treatment strategies.
During this webinar, viewers will:
- Gain an understanding of the specific molecules and pathways that are the targets for rationally designed therapies
- Learn about efforts to overcome resistance to the first FDA-approved therapy targeting a hyperactive kinase
- Review mechanisms by which tumor cells resist inhibitors that target cell survival and growth pathways
- Hear how the rewiring of cell death pathways can sensitize cells to traditional chemotherapy agents.
